Hoth Therapeutics Inc

HOTH

Company Profile

  • Business description

    Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

  • Contact

    1177 Avenue of the Americas
    5th Floor, Suite 5066
    New YorkNY10036
    USA

    T: +1 646 756-2997

    https://www.hoththerapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    3

Stocks News & Analysis

stocks

How I lost all my savings through a poor investment decision

With first timers at risk of poor investment decisions and an interest in speculative stocks, I explore my biggest investing mistake.
stocks

Our view of Nvidia / OpenAI deal

Big AI dreams as firms announce a strategic partnership.
stocks

Chart of the Week: Morningstar’s forecast for CSL’s future

We see gross margin expansion on efficiencies and limited tariff impact

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,063.4033.900.38%
CAC 407,762.2365.22-0.83%
DAX 4023,394.23272.58-1.15%
Dow JONES (US)46,121.28171.50-0.37%
FTSE 1009,207.3843.05-0.47%
HKSE26,484.6833.97-0.13%
NASDAQ22,497.8675.62-0.33%
Nikkei 22545,754.93124.620.27%
NZX 50 Index13,153.7927.52-0.21%
S&P 5006,637.9718.95-0.28%
S&P/ASX 2008,773.0035.100.40%
SSE Composite Index3,853.300.34-0.01%

Market Movers